$AXGN 8-K SEC Filings

Filed On	Filing
01 Oct 2026	8-K: Regulation FD Disclosure Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair
10 Sep 2026	8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure +1 more Axogen, Inc., a Minnesota corporation (the “Company”) confirms its agreement with BofA Securities, Inc. (“BofA Securities”), Jefferies LLC (“Jefferies”), Wells Fargo Securities, LLC (“Wells Fargo”) and each of the other Underwriters name...
29 Jul 2026	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
23 Jun 2026	8-K: Submission of Matters to a Vote of Security Holders
28 Apr 2026	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
24 Feb 2026	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
23 Jan 2026	8-K: Entry into a Material Definitive Agreement; Other Events
12 Jan 2026	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
05 Dec 2025	8-K: Departure/Election of Directors or Officers; Compensation
04 Dec 2025	8-K: Regulation FD Disclosure; Other Events
29 Oct 2025	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
25 Aug 2025	8-K: Regulation FD Disclosure
05 Aug 2025	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
20 Jun 2025	8-K: Submission of Matters to a Vote of Security Holders
08 May 2025	8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation
07 Apr 2025	8-K: Regulation FD Disclosure
04 Mar 2025	8-K: Regulation FD Disclosure
25 Feb 2025	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
10 Jan 2025	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
07 Nov 2024	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Comments